• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于血清甲状腺素、三碘甲状腺原氨酸和促甲状腺激素浓度分析的垂体-甲状腺对肌内注射促甲状腺激素释放激素的反应性。

Pituitary-thyroid responsiveness to intramuscular thyrotropin-releasing hormone based on analyses of serum thyroxine, tri-iodothyronine and thyrotropin concentrations.

作者信息

Azizi F, Vagenakis A G, Portnay G I, Rapoport B, Ingbar S H, Braverman L E

出版信息

N Engl J Med. 1975 Feb 6;292(6):273-7. doi: 10.1056/NEJM197502062920601.

DOI:10.1056/NEJM197502062920601
PMID:803298
Abstract

To develop a test of pituitary-thyroid responsiveness to thyrotropin-releasing hormone that would obviate the need for measuring serum thyrotropin, we determined serum thyrotropin, thyroxine, and tri-iodothyronine concentrations before and at frequent intervals after the intramuscular administration of 2 mg of thyrotropin-releasing hormone in normal subjects and in patients with a variety of thyroid disorders. In specimens obtained four and five hours after administration of the hormone to normal subjects, serum thyroxine concentration increased 2.4 plus or minus 0.7 mug per 100 ml (mean plus or minus S.D.) over base-line values, the magnitude of increase being greater than 1.5 mug per 100 ml in 32 of 34 subjects. Serum thyroxine concentrations after administration of thyrotropin-releasing hormone did not increase in 11 hyperthyroid patients. Of 13 with hypothyroidism, increases in 12 were 0 to 0.7 mug per 100 ml; in one the increment was 1.2 mug per 100 ml. Measurement of the serum thyroxine response to intramuscular thyrotropin-releasing hormone will usually suffice to determine the integrity of the hypothalamic-pituitary-thyroid complex.

摘要

为了开发一种垂体 - 甲状腺对促甲状腺激素释放激素反应性的检测方法,以避免测量血清促甲状腺激素的需求,我们在正常受试者和患有各种甲状腺疾病的患者中,于肌肉注射2mg促甲状腺激素释放激素之前及之后的频繁时间间隔测定血清促甲状腺激素、甲状腺素和三碘甲状腺原氨酸浓度。在向正常受试者注射激素后4小时和5小时采集的样本中,血清甲状腺素浓度比基线值每100ml增加2.4±0.7μg(平均值±标准差),34名受试者中有32名的增加幅度大于每100ml 1.5μg。11名甲状腺功能亢进患者在注射促甲状腺激素释放激素后血清甲状腺素浓度未增加。13名甲状腺功能减退患者中,12名的增加量为每100ml 0至0.7μg;1名的增量为每100ml 1.2μg。测量血清甲状腺素对肌肉注射促甲状腺激素释放激素的反应通常足以确定下丘脑 - 垂体 - 甲状腺复合体的完整性。

相似文献

1
Pituitary-thyroid responsiveness to intramuscular thyrotropin-releasing hormone based on analyses of serum thyroxine, tri-iodothyronine and thyrotropin concentrations.基于血清甲状腺素、三碘甲状腺原氨酸和促甲状腺激素浓度分析的垂体-甲状腺对肌内注射促甲状腺激素释放激素的反应性。
N Engl J Med. 1975 Feb 6;292(6):273-7. doi: 10.1056/NEJM197502062920601.
2
Repetitive administration of thyrotropin-releasing hormone results in small elevations of serum thyroid hormones and in marked inhibition of thyrotropin response.重复给予促甲状腺激素释放激素会导致血清甲状腺激素轻度升高,并显著抑制促甲状腺激素反应。
J Clin Invest. 1973 Sep;52(9):2305-12. doi: 10.1172/JCI107419.
3
The use of intramuscularly administered methyl-TRH to evaluate the pituitary-thyroid axis.使用肌肉注射甲基促甲状腺激素释放激素来评估垂体-甲状腺轴。
Horm Metab Res. 1978 May;10(3):233-6. doi: 10.1055/s-0028-1093442.
4
Serum thyrotropin responses to synthetic thyrotropin-releasing hormone in normal children and hypopituitary patients. A new test to distinguish primary releasing hormone deficiency from primary pituitary hormone deficiency.正常儿童和垂体功能减退患者血清促甲状腺激素对合成促甲状腺激素释放激素的反应。一种区分原发性释放激素缺乏和原发性垂体激素缺乏的新测试。
J Clin Invest. 1972 Feb;51(2):431-7. doi: 10.1172/JCI106829.
5
Recovery of pituitary thyrotropic function after withdrawal of prolonged thyroid-suppression therapy.
N Engl J Med. 1975 Oct 2;293(14):681-4. doi: 10.1056/NEJM197510022931402.
6
Canine and feline thyroid function assessment with the thyrotropin-releasing hormone response test.通过促甲状腺激素释放激素反应试验评估犬猫甲状腺功能
Am J Vet Res. 1984 Nov;45(11):2310-3.
7
Effect of thyrotropin-releasing factor on serum thyroid-stimulating hormone. An approach to distinguishing hypothalamic from pituitary forms of idiopathic hypopituitary dwarfism.促甲状腺素释放因子对血清促甲状腺激素的作用。一种区分特发性垂体性侏儒症下丘脑型与垂体型的方法。
J Clin Invest. 1971 Oct;50(10):2219-25. doi: 10.1172/JCI106717.
8
Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone.甲状腺激素对催乳素对促甲状腺激素释放激素反应的抑制作用。
J Clin Invest. 1973 Sep;52(9):2324-9. doi: 10.1172/JCI107421.
9
Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones.少量甲状腺激素对促甲状腺激素释放激素引起的促甲状腺激素反应的抑制作用。
J Clin Invest. 1972 Aug;51(8):2077-84. doi: 10.1172/JCI107014.
10
Serum levels of thyrotropin, prolactin, growth hormone, triiodothyronine and thyroxine after oral administration of thyrotropin releasing hormone in hypothyroid and hyperthyroid patients.甲状腺功能减退和甲状腺功能亢进患者口服促甲状腺激素释放激素后血清促甲状腺激素、催乳素、生长激素、三碘甲状腺原氨酸和甲状腺素水平。
Endokrinologie. 1976;68(2):175-82.

引用本文的文献

1
Impaired Sensitivity to Thyroid Hormones Is Associated With the Change of Abdominal Fat in Euthyroid Type 2 Diabetes Patients: A Retrospective Cohort Study.甲状腺激素敏感性受损与甲状腺功能正常的 2 型糖尿病患者腹部脂肪变化相关:一项回顾性队列研究。
J Diabetes Res. 2024 Apr 29;2024:8462987. doi: 10.1155/2024/8462987. eCollection 2024.
2
The association between the thyroid feedback quantile-based index and serum uric acid in U.S. adults.美国成年人中甲状腺反馈分位数指数与血清尿酸之间的关联。
Eur J Med Res. 2023 Jul 27;28(1):259. doi: 10.1186/s40001-023-01214-3.
3
Thyroid dysfunction in a prospectively followed series of patients with progressive systemic sclerosis.
在一组前瞻性随访的进行性系统性硬化症患者中甲状腺功能障碍
J Endocrinol Invest. 1990 Feb;13(2):161-9. doi: 10.1007/BF03349530.
4
Evaluation of the normal range of values for uptake of radioactive iodine by the thyroid gland.甲状腺摄取放射性碘正常值范围的评估。
Can Med Assoc J. 1976 Jul 3;115(1):29-35.
5
Thyroid-stimulating hormone (tsh), triiodothyronine (t3) and thyroxine (t4) response to intravenous and oral stimulation with synthetic thyrotropin-releasing hormone (trh) in young healthy adults.年轻健康成年人对合成促甲状腺激素释放激素(TRH)静脉注射和口服刺激的促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)和甲状腺素(T4)反应。
Klin Wochenschr. 1978 Jan 1;56(1):31-5. doi: 10.1007/BF01476740.
6
Comparison of thyrotropin-releasing hormone with melanocyte-stimulating-hormone-release-inhibiting factor as pentobarbital antagonists in monkeys.
Psychopharmacology (Berl). 1977 Jul 18;53(2):205-6. doi: 10.1007/BF00426494.